{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:00:47Z","timestamp":1784718047410,"version":"3.55.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Gastric cancer is a highly prevalent malignancy of the digestive tract in China. Conventional chemotherapeutic drugs and human epidermal growth factor receptor 2 (HER2)\u2011targeted agents such as trastuzumab remain limited by significant challenges in the treatment of GC, including high rates of drug resistance, significant toxicity and adverse effects, and suboptimal tolerability. The advent of antibody-drug conjugates (ADCs) has marked a paradigm shift in the therapeutic landscape. This review systematically summarises the structural design, mechanisms of action, and current clinical applications of ADCs in HER2-positive or HER2-low advanced gastric cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The present review focuses on key clinical trial data for new-generation ADCs, specifically trastuzumab deruxtecan (T-DXd) and disitamab vedotin (RC48), drawing from the DESTINY-Gastric series and the RC48-C008 study. The review systematically synthesised data on efficacy, safety profiles, resistance mechanisms, and future therapeutic directions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>New-generation ADCs have demonstrated significant improvements in objective response rates (ORR) and overall survival (OS) compared with traditional chemotherapy in later-line treatment settings. Emerging evidence also suggests the presence of activity in HER2-low-expressing populations. A systematic assessment of adverse drug reactions highlights both common events (e.g. gastrointestinal reactions, haematologic toxicity) and distinctive adverse events (e.g. interstitial lung disease), with corresponding management strategies. A comprehensive analysis of multiple resistance mechanisms, including HER2 heterogeneity, endocytic barriers, drug efflux, and target mutations, is conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The present study demonstrates that ADCs represent a transformative therapeutic modality for HER2-positive or HER2-low cases. Ongoing advancements in ADC structural optimisation, combination strategies with immune checkpoint inhibitors show great promise in terms of further improving clinical outcomes. The objective of this review is to furnish clinicians and researchers with a detailed reference for future clinical practice and investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s43046-026-00388-1","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T09:03:47Z","timestamp":1784711027000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of antibody-drug conjugates in HER2-positive and HER2-low advanced gastric cancer: a systematic review and update"],"prefix":"10.1186","volume":"38","author":[{"given":"Lili","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangwei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuona","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocong","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"3","key":"388_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"388_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.21147\/j.issn.1000-9604.2024.03.07","volume":"36","author":"Z Li","year":"2024","unstructured":"Li Z, Zhao H, Hu H, Shang H, Ren Y, Qiu W, Su H, Lyu H, Chen X. Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer. Chin J Cancer Res. 2024;36(3):306\u201321.","journal-title":"Chin J Cancer Res"},{"key":"388_CR3","doi-asserted-by":"publisher","first-page":"847835","DOI":"10.3389\/fmolb.2022.847835","volume":"9","author":"J Yu","year":"2022","unstructured":"Yu J, Fang T, Yun C, Liu X, Cai X. Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers. Front Mol Biosci. 2022;9:847835.","journal-title":"Front Mol Biosci"},{"issue":"3","key":"388_CR4","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"388_CR5","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","volume":"19","author":"C Gr\u00e1valos","year":"2008","unstructured":"Gr\u00e1valos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523\u20139.","journal-title":"Ann Oncol"},{"issue":"4","key":"388_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40265-020-01272-5","volume":"80","author":"J Palle","year":"2020","unstructured":"Palle J, Rochand A, Pernot S, Gallois C, Ta\u00efeb J, Zaanan A. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: current knowledge and future perspectives. Drugs. 2020;80(4):401\u201315.","journal-title":"Drugs"},{"issue":"10","key":"388_CR7","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.3390\/jcm12103391","volume":"12","author":"S Ariga","year":"2023","unstructured":"Ariga S. History and future of HER2-targeted therapy for advanced gastric cancer. J Clin Med. 2023;12(10):3391.","journal-title":"J Clin Med"},{"issue":"4","key":"388_CR8","doi-asserted-by":"publisher","first-page":"152882","DOI":"10.1016\/j.prp.2020.152882","volume":"216","author":"Y Xi","year":"2020","unstructured":"Xi Y, Xu C, Liu Y, Yan X, Huang C, Liu Y, Mei J, Wang Z, Liu B, Li X, Li W, Lan J, Gao P, Wu J, Zheng J, Hou Y. The age variation of HER2 immunohistochemistry positive rate in biopsy specimens of gastric cancer. Pathol Res Pract. 2020;216(4):152882.","journal-title":"Pathol Res Pract"},{"key":"388_CR9","doi-asserted-by":"publisher","first-page":"153280","DOI":"10.1016\/j.prp.2020.153280","volume":"217","author":"F Li","year":"2020","unstructured":"Li F, Meng G, Tan B, Chen Z, Ji Q, Wang X, Liu C, Niu S, Li Y, Liu Y. Relationship between HER2 expression and tumor interstitial angiogenesis in primary gastric cancer and its effect on prognosis. Pathol Res Pract. 2020;217:153280.","journal-title":"Pathol Res Pract"},{"issue":"2","key":"388_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, Farjah F, Gerdes H, Gibson MK, Hochwald S, Hofstetter WL, Ilson DH, Keswani RN, Kim S, Kleinberg LR, Klempner SJ, Lacy J, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Outlaw D, Park H, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian N, Pluchino LA. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(2):167\u201392.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"388_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13000-025-01632-3","volume":"20","author":"J Shang","year":"2025","unstructured":"Shang J, Miao J, Niu S, Sun X, Liu Y. Redefining therapeutic landscapes: clinicopathological insights into low and ultra-low HER2 expression in male breast cancer. Diagn Pathol. 2025;20(1):43.","journal-title":"Diagn Pathol"},{"issue":"1","key":"388_CR12","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1186\/s12885-025-15255-w","volume":"25","author":"K Takada","year":"2025","unstructured":"Takada K, Kashiwagi S, Nishikawa M, Kochi A, Watanabe C, Kinoshita H, Ogisawa K, Shibutani M, Morisaki T. Clinical characteristics and prognostic impact of HER2-ultralow breast cancer and tumor-infiltrating lymphocytes (TILs). BMC Cancer. 2025;25(1):1936.","journal-title":"BMC Cancer"},{"issue":"9742","key":"388_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, R\u00fcschoff J, Kang YK. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3,open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397.","journal-title":"Lancet"},{"issue":"3","key":"388_CR14","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","volume":"18","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, L\u00f3pez-Sanchez RI, Price T, Gladkov O, Stoss O, Hill J, Ng V, Lehle M, Thomas M, Kiermaier A, R\u00fcschoff J. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476\u201384.","journal-title":"Gastric Cancer"},{"issue":"3","key":"388_CR15","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10120-018-0891-1","volume":"22","author":"S Seo","year":"2019","unstructured":"Seo S, Ryu MH, Park YS, Ahn JY, Park Y, Park SR, Ryoo BY, Lee GH, Jung HY, Kang YK. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer. 2019;22(3):527\u201335.","journal-title":"Gastric Cancer"},{"issue":"11","key":"388_CR16","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/1535-7163.MCT-19-0455","volume":"18","author":"A Sampera","year":"2019","unstructured":"Sampera A, S\u00e1nchez-Mart\u00edn FJ, Arp\u00ed O, Visa L, Iglesias M, Men\u00e9ndez S, Gaye \u00c9, Dalmases A, Clav\u00e9 S, Gelabert-Baldrich M, Poulsen TT, Kragh M, Bellosillo B, Albanell J, Rovira A, Montagut C. HER-family ligands promote acquired resistance to trastuzumab in gastric cancer. Mol Cancer Ther. 2019;18(11):2135\u201345.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"388_CR17","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.dld.2022.11.023","volume":"55","author":"LG Alexis","year":"2023","unstructured":"Alexis LG, Dano H, Dekairelle AF, Van Marcke C, Van den Eynde M. Acquired microsatellite instability status and loss of HER2 positivity during treatment of gastro-esophageal junction adenocarcinoma. Dig Liver Dis. 2023;55(3):426\u20138.","journal-title":"Dig Liver Dis"},{"key":"388_CR18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1245\/s10434-013-3325-7","volume":"21","author":"K Eto","year":"2014","unstructured":"Eto K, Iwatsuki M, Watanabe M, Ida S, Ishimoto T, Iwagami S, Baba Y, Sakamoto Y, Miyamoto Y, Yoshida N, Baba H. The microRNA-21\/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab. Ann Surg Oncol. 2014;21:343\u201350.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"388_CR19","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1158\/1535-7163.MCT-16-0669","volume":"16","author":"MH Jin","year":"2017","unstructured":"Jin MH, Nam AR, Park JE, Bang JH, Bang YJ, Oh DY. Resistance mechanism against trastuzumab in HER2-positive cancer cells and its negation by Src inhibition. Mol Cancer Ther. 2017;16(6):1145\u201354.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"388_CR20","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1038\/s41467-021-23053-8","volume":"12","author":"W Shi","year":"2021","unstructured":"Shi W, Zhang G, Ma Z, Li L, Liu M, Qin L, Yu Z, Zhao L, Liu Y, Zhang X, Qin J, Ye H, Jiang X, Zhou H, Sun H, Jiao Z. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer. Nat Commun. 2021;12(1):2812.","journal-title":"Nat Commun"},{"issue":"18","key":"388_CR21","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.7150\/ijms.50563","volume":"17","author":"J Chang","year":"2020","unstructured":"Chang J, Wang Q, Bhetuwal A, Liu W. Metabolic pathways underlying GATA6 regulating Trastuzumab resistance in Gastric Cancer cells based on untargeted metabolomics. Int J Med Sci. 2020;17(18):3146\u201364.","journal-title":"Int J Med Sci"},{"issue":"1","key":"388_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12015-023-10639-6","volume":"20","author":"MC Borlongan","year":"2024","unstructured":"Borlongan MC, Saha D, Wang H. Tumor microenvironment: A niche for cancer stem cell immunotherapy. Stem Cell Reviews Rep. 2024;20(1):3\u201324.","journal-title":"Stem Cell Reviews Rep"},{"issue":"22","key":"388_CR23","doi-asserted-by":"publisher","first-page":"5493","DOI":"10.3390\/cancers15225493","volume":"15","author":"Q Pu","year":"2023","unstructured":"Pu Q, Gao H. The Role of the Tumor Microenvironment in Triple-Positive Breast Cancer Progression and Therapeutic Resistance. Cancers. 2023;15(22):5493.","journal-title":"Cancers"},{"issue":"10294","key":"388_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"},{"issue":"14","key":"388_CR25","doi-asserted-by":"publisher","first-page":"13345","DOI":"10.1007\/s00432-023-05142-x","volume":"149","author":"DHW Liu","year":"2023","unstructured":"Liu DHW, Grabsch HI, Gloor B, Langer R, Dislich B. Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases. J Cancer Res Clin Oncol. 2023;149(14):13345\u201352.","journal-title":"J Cancer Res Clin Oncol"},{"key":"388_CR26","doi-asserted-by":"publisher","first-page":"175883592098651","DOI":"10.1177\/1758835920986518","volume":"13","author":"D Kotani","year":"2021","unstructured":"Kotani D, Shitara K. Trastuzumab deruxtecan for the treatment of patients with HER2- positive gastric cancer. Ther Adv Med Oncol. 2021;13:1758835920986518.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"388_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the biological missile for targeted cancer therapy. Signal Transduct Target therapy. 2022;7(1):93.","journal-title":"Signal Transduct Target therapy"},{"issue":"5","key":"388_CR28","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00228-021-03253-3","volume":"78","author":"B Xu","year":"2022","unstructured":"Xu B. Loncastuximab tesirine: An effective therapy for relapsed or refractory diffuse large B-cell lymphoma. Eur J Clin Pharmacol. 2022;78(5):707\u201319.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"388_CR29","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3390\/cancers16040827","volume":"16","author":"A Al Sbihi","year":"2024","unstructured":"Al Sbihi A, Alasfour M, Pongas G. Innovations in antibody-drug conjugate (ADC) in the treatment of lymphoma. Cancers. 2024;16(4):827.","journal-title":"Cancers"},{"key":"388_CR30","unstructured":"Ian Ingram. FDA Approves T-DM1 (Kadcyla) for HER2-Positive Breast Cancer. 2013. https:\/\/www.cancernetwork.com\/view\/fda-approves-t-dm1-kadcyla-her2-positive-breast-cancer."},{"issue":"1","key":"388_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA. DESTINY-Breast 04 Trial Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9\u201320.","journal-title":"N Engl J Med"},{"issue":"8","key":"388_CR32","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/oncolo\/oyae151","volume":"29","author":"GU Mehta","year":"2024","unstructured":"Mehta GU, Vellanki PJ, Ren Y, Amatya AK, Mishra-Kalyani PS, Pan L, Zirkelbach JF, Pan Y, Liu J, Aungst SL, Miller CP, Shah M, Rahman NA, Theoret M, Kluetz P, Pazdur R, Beaver JA, Singh H. FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations. Oncologist. 2024;29(8):667\u201371.","journal-title":"Oncologist"},{"key":"388_CR33","first-page":"71","volume":"2024","author":"AA Almodovar Diaz","year":"2024","unstructured":"Almodovar Diaz AA, Alouch SS, Chawla Y, Gonsalves WI. The Antibody Drug Conjugate, Belantamab-Mafodotin, in the Treatment of Multiple Myeloma: A Comprehensive Review. Blood Lymphatic Cancer: Targets Therapy. 2024;2024:71\u201387.","journal-title":"Blood Lymphatic Cancer: Targets Therapy"},{"key":"388_CR34","unstructured":"Courtney F. FDA Grants Fast Track Designation to Ozuriftamab Vedotin in Recurrent\/MetastaticHNSCC. 2024. https:\/\/www.onclive.com\/view\/fda-grants-fast-track-designation-to-ozuriftamab-vedotin-in-recurrent-metastatic-hnscc."},{"key":"388_CR35","unstructured":"Center for Drug Evaluation and Research. FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervic. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisotumab-vedotin-tftv-recurrent-or-metastatic-cervical-cancer."},{"key":"388_CR36","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.2147\/CMAR.S294080","volume":"15","author":"V Agostinelli","year":"2023","unstructured":"Agostinelli V, Musacchio L, Camarda F, Salutari V, Carbone MV, Ghizzoni V, Nero C, Ricci C, Perri MT, Giudice E, Lardino S, Berardi R, Scambia G, Lorusso D. Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data. Cancer Manag Res. 2023;15:1063\u201372.","journal-title":"Cancer Manag Res"},{"key":"388_CR37","doi-asserted-by":"publisher","first-page":"117955492412907","DOI":"10.1177\/11795549241290787","volume":"18","author":"E Vlachou","year":"2024","unstructured":"Vlachou E, Johnson BA, Hoffman-Censits J. The Role of Antibody-Drug Conjugates in Urothelial Cancer: A Review of Recent Advances in the Treatment of Locally Advanced and Metastatic Urothelial Cancer. Clin Med Insights: Oncol. 2024;18:11795549241290787.","journal-title":"Clin Med Insights: Oncol"},{"issue":"25","key":"388_CR38","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020;382(25):2419\u201330.","journal-title":"N Engl J Med"},{"issue":"7890","key":"388_CR39","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Kawazoe A, Ya\u00f1ez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L, Tang Y, Wyrwicz LS, Xu J, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L, Shah S, Bhagia P, Chung HC. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727\u201330.","journal-title":"Nature"},{"issue":"4","key":"388_CR40","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1007\/s10120-021-01196-3","volume":"24","author":"K Shitara","year":"2021","unstructured":"Shitara K, Baba E, Fujitani K, Oki E, Fujii S, Yamaguchi K. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer. Gastric Cancer. 2021;24(4):780\u20139.","journal-title":"Gastric Cancer"},{"issue":"1","key":"388_CR41","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s12094-024-03534-0","volume":"27","author":"SN Wang","year":"2025","unstructured":"Wang SN, Wang YK, Zhu CY, Jiang B, Ge DF, Li YY. Significance of concurrent evaluation of HER2 gene amplification and p53 and Ki67 expression in gastric cancer tissues. Clin Transl Oncol. 2025;27(1):126\u201334.","journal-title":"Clin Transl Oncol"},{"key":"388_CR42","doi-asserted-by":"publisher","first-page":"115161","DOI":"10.1016\/j.colsurfb.2025.115161","volume":"257","author":"X Yao","year":"2026","unstructured":"Yao X, Lu Y, Shi S, Wang Y. Antibody-drug conjugates (ADCs): Smart Missiles targeting cancer therapy. Colloids Surf B Biointerfaces. 2026;257:115161.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"388_CR43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jconrel.2024.01.025","volume":"367","author":"Y Liubomirski","year":"2024","unstructured":"Liubomirski Y, Tiram G, Scomparin A, Gnaim S, Das S, Gholap S, Ge L, Yeini E, Shelef O, Zauberman A, Berger N, Kalimi D, Toister-Achituv M, Schr\u00f6ter C, Dickgiesser S, Tonillo J, Shan M, Deutsch C, Sweeney-Lasch S, Shabat D, Satchi-Fainaro R. Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker. J Control Release. 2024;367:148\u201357.","journal-title":"J Control Release"},{"issue":"14","key":"388_CR44","doi-asserted-by":"publisher","first-page":"993","DOI":"10.2174\/0118715206348204241128063329","volume":"25","author":"I Sevilla-Carrillo","year":"2025","unstructured":"Sevilla-Carrillo I, Garc\u00eda-Tercero E, Alonso-Moreno C, Moya-Lopez C. Antibody Drug Conjugates (ADCs): Shaping the Future of Precision Oncology. Anticancer Agents Med Chem. 2025;25(14):993\u20131016.","journal-title":"Anticancer Agents Med Chem"},{"issue":"3","key":"388_CR45","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10120-021-01164-x","volume":"24","author":"M Aoki","year":"2021","unstructured":"Aoki M, Iwasa S, Boku N. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective. Gastric Cancer. 2021;24(3):567\u201376.","journal-title":"Gastric Cancer"},{"issue":"5","key":"388_CR46","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","volume":"18","author":"PC Thuss-Patience","year":"2017","unstructured":"Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, Phillips GDL, van der Horst T, Harle-Yge ML, Althaus BL, Kang YK. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study. Lancet Oncol. 2017;18(5):640\u201353.","journal-title":"Lancet Oncol"},{"issue":"1","key":"388_CR47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/ajco.13243","volume":"16","author":"K Shitara","year":"2020","unstructured":"Shitara K, Honma Y, Omuro Y, Yamaguchi K, Chin K, Muro K, Nakagawa S, Kawakami S, Hironaka S, Nishina T. Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study. Asia-Pac J Clin Oncol. 2020;16(1):5\u201313.","journal-title":"Asia-Pac J Clin Oncol"},{"issue":"3","key":"388_CR48","doi-asserted-by":"publisher","first-page":"493","DOI":"10.21873\/invivo.11088","volume":"31","author":"J Watanabe","year":"2017","unstructured":"Watanabe J, Ito Y, Saeki T, Masuda N, Takano T, Takao S, Nakagami K, Tsugawa K, Nakagawa S, Kanatani K, Nakayama T. Safety evaluation of trastuzumab emtansine in Japanese patients with HER2-positive advanced breast cancer. Vivo. 2017;31(3):493\u2013500.","journal-title":"Vivo"},{"key":"388_CR49","doi-asserted-by":"publisher","first-page":"107697","DOI":"10.1016\/j.bioorg.2024.107697","volume":"151","author":"R Chen","year":"2024","unstructured":"Chen R, Ren Z, Bai L, Hu X, Chen Y, Ye Q, Hu Y, Shi J. Novel antibody-drug conjugates based on DXd-ADC technology. Bioorg Chem. 2024;151:107697.","journal-title":"Bioorg Chem"},{"issue":"4","key":"388_CR50","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s10120-022-01298-6","volume":"25","author":"K Bang","year":"2022","unstructured":"Bang K, Cheon J, Park YS, Kim HD, Ryu MH, Park Y, Moon M, Lee H, Kang YK. Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab. Gastric Cancer. 2022;25(4):794\u2013803.","journal-title":"Gastric Cancer"},{"issue":"7","key":"388_CR51","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039\u201346.","journal-title":"Cancer Sci"},{"issue":"4","key":"388_CR52","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1200\/JCO.22.00575","volume":"41","author":"K Yamaguchi","year":"2023","unstructured":"Yamaguchi K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Shimoyama T, Lee KW, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Shitara K. Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial. J Clin Oncol. 2023;41(4):816\u201325.","journal-title":"J Clin Oncol"},{"issue":"5","key":"388_CR53","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/17460441.2022.2050692","volume":"17","author":"J Kalmuk","year":"2022","unstructured":"Kalmuk J, Rinder D, Heltzel C, Lockhart AC. An overview of the preclinical discovery and development of trastuzumab deruxtecan: a novel gastric cancer therapeutic. Expert Opin Drug Discov. 2022;17(5):427\u201336.","journal-title":"Expert Opin Drug Discov"},{"issue":"7","key":"388_CR54","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"E Van Cutsem","year":"2023","unstructured":"Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, Lonardi S, Wainberg ZA, Ajani J, Chao J, Janjigian Y, Qin A, Singh J, Barlaskar F, Kawaguchi Y, Ku G. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24(7):744\u201356.","journal-title":"Lancet Oncol"},{"issue":"4","key":"388_CR55","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1056\/NEJMoa2503119","volume":"393","author":"K Shitara","year":"2025","unstructured":"Shitara K, Van Cutsem E, G\u00fcm\u00fc\u015f M, Lonardi S, de la Fouchardi\u00e8re C, Coutzac C, Dekervel J, Hochhauser D, Shen L, Mansoor W, Liu B, Fornaro L, Ryu MH, Lee J, Faustino C, Metges JP, Tabernero J, Franke F, Janjigian YY, Souza F, Jukofsky L, Zhao Y, Kamio T, Zaanan A, Pietrantonio F. Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. N Engl J Med. 2025;393(4):336\u201348.","journal-title":"N Engl J Med"},{"issue":"1","key":"388_CR56","doi-asserted-by":"publisher","first-page":"16891","DOI":"10.1038\/s41598-021-96521-2","volume":"11","author":"S Nakajima","year":"2021","unstructured":"Nakajima S, Mimura K, Matsumoto T, Min T AK, Ito M, Nakano H, Neupane P, Kanke Y, Okayama H, Saito M, Momma T, Watanabe Y, Hanayama H, Hayase S, Saze Z, Kono K. The effects of T-DXd on the expression of HLA class I and chemokines CXCL9\/10\/11 in HER2-overexpressing gastric cancer cells. Sci Rep. 2021;11(1):16891.","journal-title":"Sci Rep"},{"key":"388_CR57","doi-asserted-by":"publisher","first-page":"103404","DOI":"10.1016\/j.eclinm.2025.103404","volume":"87","author":"Z Peng","year":"2025","unstructured":"Peng Z, Chen P, Lu J, Wan Y, Zheng Y, Ye F, Yang J, Liu Y, Pan H, Sun M, Fan Q, Yuan Y, Chen K, Sun Z, Tian H, Xia Y, Shen L. Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2-positive locally advanced\/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trial. EclinicalMedicine. 2025;87:103404.","journal-title":"EclinicalMedicine"},{"issue":"9","key":"388_CR58","doi-asserted-by":"publisher","first-page":"8019","DOI":"10.3390\/curroncol30090582","volume":"30","author":"JW Henning","year":"2023","unstructured":"Henning JW, Brezden-Masley C, Gelmon K, Chia S, Shapera S, McInnis M, Rayson D, Asselah J. Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective. Curr Oncol. 2023;30(9):8019\u201338.","journal-title":"Curr Oncol"},{"issue":"1","key":"388_CR59","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","volume":"29","author":"F Shi","year":"2022","unstructured":"Shi F, Liu Y, Zhou X, Shen P, Xue R, Zhang M. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy. Drug Delivery. 2022;29(1):1335\u201344.","journal-title":"Drug Delivery"},{"issue":"4","key":"388_CR60","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10120-021-01168-7","volume":"24","author":"Y Xu","year":"2021","unstructured":"Xu Y, Wang Y, Gong J, Zhang X, Peng Z, Sheng X, Mao C, Fan Q, Bai Y, Ba Y, Jiang D, Yang F, Qi C, Li J, Wang X, Zhou J, Lu M, Cao Y, Yuan J, Liu D, Wang Z, Fang J, Shen L. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody\u2013MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer. 2021;24(4):913\u201325.","journal-title":"Gastric Cancer"},{"issue":"11","key":"388_CR61","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/cac2.12214","volume":"41","author":"Z Peng","year":"2021","unstructured":"Peng Z, Liu T, Wei J, Wang A, He Y, Yang L, Zhang X, Fan N, Luo S, Li Z, Gu K, Lu J, Xu J, Fan Q, Xu R, Zhang L, Li E, Sun Y, Yu G, Bai C, Liu Y, Zeng J, Ying J, Liang X, Xu N, Gao C, Shu Y, Ma D, Dai G, Li S, Deng T, Cui Y, Fang J, Ba Y, Shen L. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun. 2021;41(11):1173\u201382.","journal-title":"Cancer Commun"},{"key":"388_CR62","doi-asserted-by":"crossref","unstructured":"Nicol\u00f2 E, Giugliano F, Ascione L, Tarantino P, Corti C, Tolaney SM, Cristofanilli M. Curigliano G. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treat Rev. 2022;106:102395.","DOI":"10.1016\/j.ctrv.2022.102395"},{"issue":"1","key":"388_CR63","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S1470-2045(16)30631-3","volume":"18","author":"SJ Luen","year":"2017","unstructured":"Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S, Loi S. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol. 2017;18(1):52\u201362.","journal-title":"Lancet Oncol"},{"issue":"1","key":"388_CR64","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1186\/s12885-023-11735-z","volume":"23","author":"C Nie","year":"2023","unstructured":"Nie C, Xu W, Guo Y, Gao X, Lv H, Chen B, Wang J, Liu Y, Zhao J, Wang S, He Y, Chen X. Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study. BMC Cancer. 2023;23(1):1239.","journal-title":"BMC Cancer"},{"key":"388_CR65","doi-asserted-by":"publisher","first-page":"102415","DOI":"10.1016\/j.eclinm.2023.102415","volume":"68","author":"Y Wang","year":"2024","unstructured":"Wang Y, Gong J, Wang A, Wei J, Peng Z, Wang X, Zhou J, Qi C, Liu D, Li J, Lu M, Lu Z, Cao Y, Yuan J, Zhang R, Fang J, Zhang X, Shen L. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial. Eclinicalmedicine. 2024;68:102415.","journal-title":"Eclinicalmedicine"},{"issue":"1","key":"388_CR66","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1038\/s41598-025-86504-y","volume":"15","author":"S Dong","year":"2025","unstructured":"Dong S, Wei C, Wang X, Yang X, Shen W, Li S, Xu J, Ma Y, Bie L, Yu W, Li N. A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer. Sci Rep. 2025;15(1):2232.","journal-title":"Sci Rep"},{"key":"388_CR67","doi-asserted-by":"crossref","unstructured":"Qu F, Lu R, Wu X, Liu Q, Zha M, Li H, Yuan Y, Han Z, Cai D, Huang X, Yin Y, Li. W. Efficacy and safety of RC48-ADC in HER2-positive and HER2-low metastatic breast cancer: a multicenter, real-world study. Front Oncol. 2024;14:1435485.","DOI":"10.3389\/fonc.2024.1435485"},{"issue":"5","key":"388_CR68","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/1078-0432.CCR-23-1725","volume":"30","author":"Q Wei","year":"2024","unstructured":"Wei Q, Yang T, Zhu J, Zhang Z, Yang L, Zhang Y, Hu C, Chen J, Wang J, Tian X, Shimura T, Fang J, Ying J, Fan M, Guo P, Cheng X. Spatiotemporal Quantification of HER2-targeting Antibody-Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration. Clin Cancer Res. 2024;30(5):984\u201397.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"388_CR69","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1158\/1535-7163.MCT-19-1004","volume":"19","author":"L Skidmore","year":"2020","unstructured":"Skidmore L, Sakamuri S, Knudsen NA, Hewet AG, Milutinovic S, Barkho W, Biroc SL, Kirtley J, Marsden R, Storey K, Lopez I, Yu W, Fang SY, Yao S, Gu Y, Tian F. ARX788, a site-specific anti-HER2 antibody\u2013drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1\u2013resistant breast and gastric cancers. Mol Cancer Ther. 2020;19(9):1833\u201343.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"388_CR70","doi-asserted-by":"publisher","first-page":"100814","DOI":"10.1016\/j.xcrm.2022.100814","volume":"3","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Qiu MZ, Wang JF, Zhang YQ, Shen A, Yuan XL, Zhang T, Wei XL, Zhao HY, Wang DS, Zhao Q, Xiong GZ, Ji YP, Liang XJ, Xia G, Xu RH. Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma. Cell Rep Med. 2022;3(11):100814.","journal-title":"Cell Rep Med"},{"issue":"8","key":"388_CR71","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.drudis.2021.06.012","volume":"26","author":"HP Yao","year":"2021","unstructured":"Yao HP, Zhao H, Hudson R, Tong XM, Wang MH. Duocarmycin-based antibody\u2013drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: pharmaceutical strategy and clinical progress. Drug Discovery Today. 2021;26(8):1857\u201374.","journal-title":"Drug Discovery Today"},{"key":"388_CR72","doi-asserted-by":"crossref","unstructured":"Nadal-Serrano M, Morancho B, Escriv\u00e1-de-Roman\u00ed S, Morales CB, Luque A, Escorihuela M, Espinosa Bravo M, Peg V, Dijcks FA, Dokter WHA, Cort\u00e9s J, Saura C, Arribas J. The second generation antibody-drug conjugate SYD985 overcomes resistances to T-DM1. Cancers. 2020;12(3): 670.","DOI":"10.3390\/cancers12030670"},{"issue":"8","key":"388_CR73","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","volume":"20","author":"U Banerji","year":"2019","unstructured":"Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019;20(8):1124\u201335.","journal-title":"Lancet Oncol"},{"issue":"3","key":"388_CR74","first-page":"175","volume":"4","author":"H Li","year":"2021","unstructured":"Li H, Zhang X, Xu Z, Li L, Liu W, Dai Z, Zhao Z, Xiao L, Li H, Hu C. Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors. Antib Ther. 2021;4(3):175\u201384.","journal-title":"Antib Ther"},{"key":"388_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr3621","volume":"16","author":"M Barok","year":"2014","unstructured":"Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16:1\u201312.","journal-title":"Breast Cancer Res"},{"key":"388_CR76","doi-asserted-by":"publisher","first-page":"114096","DOI":"10.1016\/j.ejca.2024.114096","volume":"205","author":"W Qu","year":"2024","unstructured":"Qu W, Fu C, Han W, Luo H, Quan J, Chen L, Liao Y, Hu C, Hu H, Niu Y, Xu D, Chen M, Chen J, Liu Y, Chen G, Luo Z, Shi B, Sun Y, Zhou F, Zhou A. A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma. Eur J Cancer. 2024;205:114096.","journal-title":"Eur J Cancer"},{"key":"388_CR77","unstructured":"ClinicalTrials.gov. A Study of MRG002 in the Treatment of Patients with HER2-positive Advanced Solid Tumors [EB\/OL]. (2021-12-03)[2023-04-15]. https:\/\/clinicaltrials.gov\/ct2\/show\/. NCT04941339."},{"key":"388_CR78","unstructured":"ClinicalTrials.gov. A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric\/Gastroesophageal Junction (GEJ) Cancer[EB\/OL]. (2021-05)[2024-12-31]. https:\/\/clinicaltrials.gov\/ct2\/show\/. NCT04492448."},{"key":"388_CR79","unstructured":"ClinicalTrials.gov. A Study of MRG002 in the Treatment of HER2-positive\/HER2-low Locally Advanced or Metastatic Gastric\/Gastroesophageal Junction Cancer[EB\/OL].(2022-02-23)[2023-04-15]. https:\/\/clinicaltrials.gov\/ct2\/show\/. NCT05141747."},{"issue":"6","key":"388_CR80","doi-asserted-by":"publisher","first-page":"e0326691","DOI":"10.1371\/journal.pone.0326691","volume":"20","author":"T Zhang","year":"2025","unstructured":"Zhang T, Xu J, Yin J, Gao Y, Zheng H, Fu B, Sun J, Xu Z, Tu S, Mao Y, Wen W, Qu B, You L, Xue Z, Sun X, Cao D, Feng J, Hu M, He F. SHR-A1811, a novel anti-HER2 antibody-drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles. PLoS ONE. 2025;20(6):e0326691.","journal-title":"PLoS ONE"},{"issue":"29","key":"388_CR81","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1200\/JCO.23.02044","volume":"42","author":"H Yao","year":"2024","unstructured":"Yao H, Yan M, Tong Z, Wu X, Ryu MH, Park JJ, Kim JH, Zhong Y, Zhao Y, Voskoboynik M, Yin Y, Liu K, Kaubisch A, Liu C, Zhang J, Wang S, Im SA, Ganju V, Barve M, Li H, Ye C, Roy AC, Bai LY, Yen CJ, Gu S, Lin YC, Wu L, Bao L, Zhao K, Shen Y, Rong S, Zhu X, Song E. Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing\/mutated advanced solid tumors: A global phase 1, multi-center, first-in-human study. J Clin Oncol. 2024;42(29):3453\u201365.","journal-title":"J Clin Oncol"},{"key":"388_CR82","doi-asserted-by":"publisher","first-page":"S478","DOI":"10.1016\/j.annonc.2023.09.1870","volume":"34","author":"J Li","year":"2023","unstructured":"Li J, Luo S, Liu T, Dong L, Yuan X, Feng J, Wang Y, Deng Y, Chen J, Zhang M. M 684P Phase I trial of SHR-A1811 in HER2-expressing advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) and colorectal cancer (CRC). Ann Oncol. 2023;34:S478.","journal-title":"Ann Oncol"},{"issue":"11","key":"388_CR83","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1111\/jcpt.13777","volume":"47","author":"Z Guo","year":"2022","unstructured":"Guo Z, Ding Y, Wang M, Liu J, Zhai Q, Du Q. Safety of trastuzumab deruxtecan: A meta-analysis and pharmacovigilance study. J Clin Pharm Ther. 2022;47(11):1837\u201344.","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"388_CR84","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22(8):641\u201361.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"388_CR85","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1186\/s12885-022-10015-6","volume":"22","author":"H Xu","year":"2022","unstructured":"Xu H, Zhang H, Guo W, Zhong X, Sun J, Zhang T, Wang Z, Ma X. Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials. BMC Cancer. 2022;22(1):923.","journal-title":"BMC Cancer"},{"issue":"S17","key":"388_CR86","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1002\/cncr.35475","volume":"130","author":"C Xu","year":"2024","unstructured":"Xu C, Chen Z, Xia Y, Shi Y, Fu P, Chen Y, Wang X, Zhang L, Li H, Chen W, Fu J, Huang L, Shu J, Wang O, Wu W, Xie B, Wang T, Zhang W, Shen S, Li Q, Luo T, Zhang B, Xie Y, Wang H, Wang Q, Wang W, Li Z, Song Z, Fang W, Zhong W, Zhang Y, Zhan P, Liu H, Lv T, Miao L, Min L, Wang F, Meng R, Zhu Y, Wang L, Wan B, Wang D, Hao Y, Zhou J, Huang L, Zhang Z, Lv D, Fang M, Lu Y, Si L, Song Y, Wang X. Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease\/pneumonitis: An expert consensus in China. Cancer. 2024;130(S17):3054\u201366.","journal-title":"Cancer"},{"issue":"9","key":"388_CR87","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40265-022-01736-w","volume":"82","author":"Z Abuhelwa","year":"2022","unstructured":"Abuhelwa Z, Alloghbi A, Alqahtani A, Nagasaka M. Trastuzumab Deruxtecan-Induced Interstitial Lung Disease\/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review. Drugs. 2022;82(9):979\u201387.","journal-title":"Drugs"},{"key":"388_CR88","doi-asserted-by":"publisher","first-page":"102378","DOI":"10.1016\/j.ctrv.2022.102378","volume":"106","author":"SM Swain","year":"2022","unstructured":"Swain SM, Nishino M, Lancaster LH, Li BT, Nicholson AG, Bartholmai BJ, Naidoo J, Schumacher-Wulf E, Shitara K, Tsurutani J, Conte P, Kato T, Andre F, Powell CA. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev. 2022;106:102378.","journal-title":"Cancer Treat Rev"},{"key":"388_CR89","doi-asserted-by":"publisher","first-page":"e2300391","DOI":"10.1200\/PO.23.00391","volume":"7","author":"M Nishino","year":"2023","unstructured":"Nishino M, Kusumoto M, Bankier AA, Kurihara Y, Zhang L, Rasheed Z, Meinhardt G, Arunachalam M, Taitt C, Wang Q, Powell CA. Trastuzumab Deruxtecan\u2013Related Interstitial Lung Disease\/Pneumonitis: Computed Tomography Imaging Patterns to Guide Diagnosis and Management. JCO Precis Oncol. 2023;7:e2300391.","journal-title":"JCO Precis Oncol"},{"key":"388_CR90","doi-asserted-by":"publisher","first-page":"104741","DOI":"10.1016\/j.breast.2026.104741","volume":"86","author":"X Liu","year":"2026","unstructured":"Liu X, Yin S, Li X, Nie J. Focusing on toxicity management: Challenges and strategies for HER2-targeted antibody-drug conjugates in breast cancer. Breast. 2026;86:104741.","journal-title":"Breast"},{"issue":"11","key":"388_CR91","doi-asserted-by":"publisher","first-page":"e2540336","DOI":"10.1001\/jamanetworkopen.2025.40336","volume":"8","author":"L Seth","year":"2025","unstructured":"Seth L, Bhave A, Kollapaneni S, Shah V, Nahle T, Blaes A, Dent S, Hurvitz SA, Guha A. Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast Cancer: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2025;8(11):e2540336.","journal-title":"JAMA Netw Open"},{"issue":"38","key":"388_CR92","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1080\/14796694.2024.2407756","volume":"20","author":"Z Zalaquett","year":"2024","unstructured":"Zalaquett Z, Rita Hachem MC, Assi A, Mohanna R, Farhat M, Noujaim C, Kourie HR. Cardiac toxicity of HER-2 targeting antibody-drug conjugates: overview and clinical implications. Future Oncol. 2024;20(38):3151\u201367.","journal-title":"Future Oncol"},{"key":"388_CR93","doi-asserted-by":"publisher","first-page":"1698458","DOI":"10.3389\/fimmu.2026.1698458","volume":"17","author":"J Zhou","year":"2026","unstructured":"Zhou J, Wang H, Xie H, Xu X, Xiao H. Ocular toxicity associated with antibody-drug conjugates in cancer therapy: a comprehensive review. Front Immunol. 2026;17:1698458.","journal-title":"Front Immunol"},{"issue":"11","key":"388_CR94","doi-asserted-by":"publisher","first-page":"102117","DOI":"10.1016\/j.ijgc.2025.102117","volume":"35","author":"EA Ciliberti","year":"2025","unstructured":"Ciliberti EA, Calleja-Holgado FJ, Lheureux S, Van Gorp T, Colombo I, Madariaga A. Safety of antibody-drug conjugates in gynecologic cancers: current evidence and management approaches. Int J Gynecol Cancer. 2025;35(11):102117.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"388_CR95","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s13691-020-00412-8","volume":"9","author":"S Hirose","year":"2020","unstructured":"Hirose S, Moriwaki T, Yamaura M, Suganuma D, Tajima H, Sato M, Enami C, Yamada T, Yamamoto Y, Sakamoto N, Hyodo I. A case of advanced gastric cancer showing HER2 positivity after chemotherapy. Int Cancer Conf J. 2020;9(3):112\u20135.","journal-title":"Int Cancer Conf J"},{"issue":"197","key":"388_CR96","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.24976\/Discov.Med.202537197.95","volume":"37","author":"H Shi","year":"2025","unstructured":"Shi H, Liu LQ, Qin YH, Song XL, Wen XW, Wang LG, Liu B, Sun X, Chai J, Wang SJ, Liu K. Improved Sampling Method to Enhance the Positive Rate of HER2 Detection in Gastric Cancer. Discov Med. 2025;37(197):1074\u201381.","journal-title":"Discov Med"},{"issue":"1","key":"388_CR97","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13000-022-01230-7","volume":"17","author":"C Xu","year":"2022","unstructured":"Xu C, Sun M, Jin M, Li Z, Qin R, Ren G, Sun W, Chen L, Luan L, Liu Y, Jiang D, Chen L, Luo R, Hou Y. Dual block HER2 assessment increased HER2 immunohistochemistry positive rate in resected specimens of gastric cancer: a prospective multicenter clinical trial from China. Diagn Pathol. 2022;17(1):54.","journal-title":"Diagn Pathol"},{"issue":"4","key":"388_CR98","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/cas.70319","volume":"117","author":"Y Murase","year":"2026","unstructured":"Murase Y, Nanjo S, Arai S, Kondo S, Koba H, Liu Y, Fukuda K, Sato S, Kinoshita J, Inaki N, Ueda T, Nomura S, Tambo Y, Shimizu T, Horie M, Maeda D, Wong RW, Hosomichi K, Kobayashi T, Watanabe S, Yamamura K, Ohkura N, Abo M, Yano S. Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2-Positive Cancers. Cancer Sci. 2026;117(4):996\u20131009.","journal-title":"Cancer Sci"},{"issue":"10","key":"388_CR99","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-24-2771","volume":"31","author":"RO Abelman","year":"2025","unstructured":"Abelman RO, Wu B, Barnes H, Medford A, Norden B, Putur A, Bitman E, Thant W, Liu T, Weipert C, Fell G, Spring LM, Wander SA, Moy B, Vidula N, Isakoff SJ, Varkaris A, Juric D, Corcoran RB, Ellisen LW, Bardia A. TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2025;31(10):1966\u201374.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00388-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-026-00388-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00388-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:01:54Z","timestamp":1784714514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43046-026-00388-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["388"],"URL":"https:\/\/doi.org\/10.1186\/s43046-026-00388-1","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"19 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"49"}}